SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Comment Letter for BioRestorative Therapies, Inc. (BRTX) (CIK 0001505497) (BRTX) — Feb 10, 2023

BioRestorative Therapies, Inc. (BRTX) (CIK 0001505497)
Date: Feb. 10, 2023 · CIK: 0001505497 · Accession: 0000000000-23-001435

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-269631

Date
February 10, 2023
Author
Lance Alstodt
Form
UPLOAD
Company
BioRestorative Therapies, Inc. (BRTX) (CIK 0001505497)

Letter

United States securities and exchange commission logo February 10, 2023 Lance Alstodt President and Chief Executive Officer BioRestorative Therapies, Inc. 40 Marcus Drive, Suite One Melville, New York 11747 Re:BioRestorative Therapies, Inc. Registration Statement on Form S-3 Filed February 7, 2023 File No. 333-269631 Dear Lance Alstodt: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jane Park at 202-551-7439 with any questions. Sincerely, Division of Corporation Finance Office of Industrial Applications and Services cc: Fred Skolnik, Esq.

Show Raw Text
United States securities and exchange commission logo
February 10, 2023
Lance Alstodt
President and Chief Executive Officer
BioRestorative Therapies, Inc.
40 Marcus Drive, Suite One
Melville, New York 11747
Re:BioRestorative Therapies, Inc.
Registration Statement on Form S-3
Filed February 7, 2023
File No. 333-269631
Dear Lance Alstodt:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Jane Park at 202-551-7439 with any questions.
Sincerely,
Division of Corporation Finance
Office of Industrial Applications and
Services
cc:       Fred Skolnik, Esq.